High-impact content drives HCP engagement. In the last year, biopharmas created significantly more content. Yet, of all the content created, 76% is rarely or never used in Europe. This indicates a need for companies to focus their content strategy on developing fewer assets that are proven effective in advancing relevant engagements with HCPs.